Format

Send to

Choose Destination
Am Heart J. 2008 Sep;156(3):528-536, 536.e1-5. doi: 10.1016/j.ahj.2008.05.015. Epub 2008 Jul 31.

Baseline characteristics of patients with diabetes and coronary artery disease enrolled in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial.

Collaborators (417)

Brooks MM, Kelley D, Orchard TJ, Rana J, Thomas SB, Tyrrell KS, Holubkov R, Averbach F, Crow SW, MacGregor JM, O'Neal SM, Pitluga K, Sansing V, Tranchine M, Hardison R, Kip K, Lu J, Lombardero M, Janiszewski S, Protivnak D, Reiser S, Barton S, Kushner Y, Michael O, Martin JP, Kania C, Kania M, O'Donnell J, Maxwell RA, Goldberg S, Rosenberg Y, Desvigne-Nickens P, Ershow A, Gordon D, Paltoo D, Jones TL, Hueb W, Ramires J, Lopes N, Wajchenberg B, Martinez EE, Oliveira SA, Betti R, Schwartz L, Steiner G, Barolet A, Groenewoud Y, Camelon K, Mighton L, O'Rourke R, Blodgett J, Sako E, Nicastro J, Prescott R, Rihal C, Kennedy F, Barsness G, Basu A, Clavell A, Frye R, Holmes DR Jr, Lerman A, Mullaney C, Reeder G, Rizza R, Schaff H, Smith S, Somers V, Sundt T, Ting H, Wright RS, Helgemoe P, Lesmeister D, Rolbiecki D, Lepe-Montoya L, Escobedo J, Barraza R, Baleón R, Campos A, García P, Lezama C, Miramontes C, Ocampo S, Peñafiel JV, Valdespino A, Verdín R, Albarrán H, Ayala F, Chávez E, Murillo H, Buitrón LV, Rico-Verdin B, Ramanathan K, Solomon S, Weinman D, Wall B, Douglas L, Touchstone T, Bourassa M, Tardif JC, Chiasson JL, Lavoie MA, Langelier H, Foucher S, Trudel J, Monrad S, Srinivas V, Zonszein J, Crandall J, Duffy H, Vartolomei E, King S 3rd, Jacobs C, Robertson D, LaCorte J, Mock M, Porter M, Rogers W, Ovalle F, Bell D, Misra VK, Hillegass WB, Aqel R, Pierce P, Smith M, Saag L, Vaughn A, Smith D, Grimes T, Rolli S, Hill R, Barrett BD, Morehead C, Doss K, Davidson CJ, Molitch M, Beohar N, Goodreau L, Massaro E, Arroyo F, Pavlickova L, Neuzil P, Stehlíková S, Benedik J, Coling L, Davies R, Glover C, LeMay M, Mesana T, Ooi TC, Silverman M, Sorisky A, Favreau C, McClinton S, Weiss M, Weiss I, Saulle L, Kannam H, Kurylas JC, Vasi L, Douglas J Jr, Ghazzal Z, Sperling L, King S 3rd, Dayamani P, Gebhart S, Basu S, Helmy T, Tangpricha V, Hyde P, Jenkins M, Kent K, Suddath W, Magee M, Julien-Williams P, Reed V, Nassar C, Dagenais G, Garceau C, Auger D, Buller C, Elliott T, Ramanathan K, Fox R, Kolesniak D, Attubato M, Feit F, Richardson S, Pena-Singh I, Slater J, Amendola A, Vargas B, Gray SC, Regan D, Tsapatsaris N, Woods B, Cushing G, Rutter M, Singh P, DesRochers G, Woodhead G, Gannon D, Campbell NS, Ragosta M, Sarembock I, Barrett E, Powers E, Jahn L, Murie K, Das G, Sigurdsson G, White C, Bantle J, Redmon JB, Kwong C, Tamis-Holland J, Albu J, Hochman JS, Slater J, Wilentz J, Frances S, Tormey D, Pepine C, Smith K, Kennedy L, Brezner K, Curry T, Bleyer F, Albert S, Mooradian A, Plummer S, Fuentes F, Robles R, Lavis V, Gomez J, Underwood C, Fulton MS, Ramirez JG, Merta J, Scott G, Krishnaswami A, Dowdell L, Berkheimer S, Greenbaum A, Whitehouse F, Pangilinan R, Mann K, Jacobs A, Sternthal E, Ebner S, Beardsley P, Schneider D, Pratley R, Cefalu W, Schnure J, Rowen M, Tilton L, Niederman A, Mata C, Kellerman T, Farmer J, Garber A, Kleiman N, Howard N, Nichols D, Pool M, Granger C, Feinglos M, Adams G, Green J, Druken B, Underwood D, Stafford JL, Donner T, Laskey W, Beach D, Lopez J, Davis A, Faxon D, Reutrakul S, Bayer E, Marroquin O, Cohen H, Korytkowski M, Koerbel G, Baxendell L, Rosenfelder D, DeRiso L, Farrell C, Vita T, Bach R, Krone R, Makan M, McGill J, Recklein C, Luepke KM, Clifton MJ, Farkouh M, Kim M, Smith DA, Guzman I, Travis A, O'Keefe J, Forker A, Isley W, Marso SP, Moe R, Captain B, Kennedy P, Rosson M, Long A, Bates E, Herman W, Pop-Busui R, Duvernoy C, Stevens M, Luciano A, Majors C, Gottlieb SH, Rodriguez A, Herr M, Williams D, Smith RJ, Abbott JD, Laufgraben MJ, Grogan M, Muratori J, Habib G, Marcelli M, Mikati I, Cordero E, Caldwell G, Schechter D, Lorber D, August P, Brown M, Depree P, Huber K, Hanusch-Enserer U, Jordanova N, Cilesiz D, Vogel B, McCallister B Jr, Mandagere K, Kleerekoper M, Urbanic R, Bengston J, Kong BK, Pruitt A, Sanfield J, Carulli C, Churley-Strom R, Magorien R, Osei K, Boyer CC, Lee R, Palumbo P, Roston S, Wisbey J, Alderman E, Ikeno F, Schwarzkopf A, Steffes M, Nowicki M, Bucksa J, Chaitman B, Eckstein J, Bertram T, Hlatky MA, Boothroyd DB, Melsop KA, Sobel BE, Rowen M, Neimane D, Iskandrian AE, Schaaf MB, Genuth S, Bongarno T, Nesto R, August P, Hultberg K, Gottlieb SH, Orchard TJ, Pambianco G, Lombardero M, Frye RL, Brooks MM, Desvigne-Nickens P, Ershow A, Genuth S, Goldberg S, Gordon D, Hardison R, Jones TL, Kelsey S, Nesto R, Orchard T, Paltoo D, Rosenberg Y, Ryan T, Ryan T, Brown R, Friesinger G, Horton E, Mason J, Virmani R, Wechsler L, Bairey-Merz CN, Kennedy JW, Gordon D, Antman E, Colwell J, Fowler S, Furberg C, Goldman L, Jennings B, Rankin S.

Author information

1
University of Pittsburgh, GSPH, A530 Crabtree Hall, Pittsburgh, PA 15261, USA. mbrooks@pitt.edu

Abstract

BACKGROUND:

The Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial was undertaken to determine whether early revascularization intervention is superior to deferred intervention in the presence of aggressive medical therapy and whether antidiabetes regimens targeting insulin sensitivity are more or less effective than regimens targeting insulin provision in reducing cardiovascular events among patients with type 2 diabetes mellitus and stable coronary artery disease (CAD).

METHODS:

The BARI 2D trial is a National Institutes of Health-sponsored randomized clinical trial with a 2 x 2 factorial design. Between 2001 and 2005, 49 clinical sites in North America, South America, and Europe randomized 2,368 patients. At baseline, the trial collected data on clinical history, symptoms, and medications along with centralized evaluations of angiograms, electrocardiograms, and blood and urine specimens.

RESULTS:

Most of the BARI 2D patients were referred from the cardiac catheterization laboratory (54%) or cardiology clinic (27%). Of the randomized participants, 30% were women, 34% were minorities, 61% had angina, and 67% had multiregion CAD. Moreover, 29% had been treated with insulin, 58% had hemoglobin A(1c) >7.0%, 41% had low-density lipoprotein cholesterol >or=100 mg/dL, 52% had blood pressure >130/80 mm Hg, and 56% had body mass index >or=30 kg/m(2).

CONCLUSIONS:

Baseline characteristics in BARI 2D are well balanced between the randomized treatment groups, and the clinical profile of the study cohort is representative of the target population. As a result, the BARI 2D clinical trial is in an excellent position to evaluate alternative treatment approaches for diabetes and CAD.

PMID:
18760137
PMCID:
PMC2701266
DOI:
10.1016/j.ahj.2008.05.015
[Indexed for MEDLINE]
Free PMC Article

Publication types, MeSH terms, Substances, Grant support

Publication types

MeSH terms

Substances

Grant support

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center